Journal Article

DKFZ-2019-02341

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png Time-to-progression after front-line fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy for chronic lymphocytic leukaemia: a retrospective, multicohort study.

Herling, C. D. ; Coombes, K. R. ; Benner, A.DKFZ* ; Bloehdorn, J. ; Barron, L. L. ; Abrams, Z. B. ; Majewski, T. ; Bondaruk, J. E. ; Bahlo, J. ; Fischer, K. ; Hallek, M. ; Stilgenbauer, S. ; Czerniak, B. A. ; Oakes, C. C. ; Ferrajoli, A. ; Keating, M. J. ; Abruzzo, L. V.

2019
The Lancet Publ. Group London

This record in other databases:  

Please use a persistent id in citations: doi:10.1016/S1470-2045(19)30503-0

Abstract: Time-to-progression after front-line fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy for chronic lymphocytic leukaemia: a retrospective, multicohort study.

Note: 20(11):1576-1586

---

Contributing Institute(s):

1. Biostatistik (C060)

Research Program(s):

1. 313 - Cancer risk factors and prevention (POF3-313) (POF3-313)

Appears in the scientific report 2019

---

Database coverage:
; Clarivate Analytics Master Journal List ; Current Contents - Clinical Medicine ; Ebsco Academic Search ; IF >= 30 ; JCR ; NCBI Molecular Biology Database ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection

---